Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies

doi:10.3760/cma.j.issn.1673-422X.2017.04.020

Abstract

Abstract: In recent years, the research hot in the field of solid tumor and blood tumor focuses on the myeloid-derived suppressor cells (MDSCs). In tumors, MDSCs not only exert immunosuppression by inhibiting T cell proliferation, destroying the functions of natural killer cells and recruiting regulatory T cells, but also play non-immunosuppression roles in the promotion of angiogenesis and tumor metastasis. All of these hinder the anti-tumor therapy, and particularly affect the curative effect, which are related with a poor clinical prognosis. MDSCs can be used as prognostic markers, which provide new targets for immunotherapy.

Key words: Immunosuppressive agents, Therapy, Myeloid-derived suppressor cells

Liu Jingjing, Jin Caibao, Xu Xiuwen, Zhu Xiaojian, Meng Li.. Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies[J]. Journal of International Oncology, 2017, 44(4): 313-316.

References

［1］ Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment［J］. Trends Immunol, 2016, 37(3): 208-220. DOI: 10.1016/j.it.2016.01.004. ［2］ De Veirman K, Van Valckenborgh E, Lahmar Q, et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies［J］. Front Oncol, 2014, 4: 349. DOI: 10.3389/fonc.2014.00349. ［3］ Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cyto-metry: results from an interim study［J］. Cancer Immunol Immuno-ther, 2016, 65(2): 161-169. DOI: 10.1007/s00262-015-1782-5. ［4］ Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment［J］. Adv Cancer Res, 2015, 128: 95-139. DOI: 10.1016/bs.acr.2015.04.002. ［5］ Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host［J］. Cancer Res, 2006, 66(2): 1123-1131. DOI: 10.1158/0008-5472. ［6］ Leonard W, Dufait I, Schwarze JK, et al. Myeloidderived suppressor cells reveal radioprotective properties through arginase-induced larginine depletion［J］. Radiother Oncol, 2016, 119(2): 291-299. DOI: 10.1016/j.radonc.2016.01.014. ［7］ Favaloro J, Liyadipitiya T, Brown R, et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma［J］. Leuk Lymphoma, 2014, 55(12): 2893-2900. DOI: 10.3109/10428194.2014.904511. ［8］ Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis［J］. Cancer Res, 2013, 73(15): 46064610. DOI: 10.1158/0008-5472.CAN-13-0305. ［9］ Gallamini A, Di Raimondo F, La Nasa G, et al. Standard therapies versus novel therapies in Hodgkin lymphoma［J］. Immunol Lett, 2013, 155(12): 56-59. DOI: 10.1016/j.imlet.2013.09.011. ［10］ Liu J, Zhou Y, Huang Q, et al. CD14+HLA-DRlow/- expression: a novel prognostic factor in chronic lymphocytic leukemia［J］. Oncol Lett, 2015, 9(3): 1167-1172. DOI: 10.3892/ol.2014.2808. ［11］ Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs［J］. Blood, 2014, 124(5): 750-760. DOI: 10.1182/blood-2013-12-546416. ［12］ Christiansson L, Sderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia［J］. PLoS One, 2013, 8(1): e55818. DOI: 10.1371/journal.pone.0055818. ［13］ Giallongo C, Parrinello N, Brundo MV, et al. Myeloid derived suppressor cells in chronic myeloid leukemia［J］. Front Oncol, 2015, 5: 107. DOI: 10.3389/fonc.2015.00107. ［14］ Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome［J］. Oncoimmunology, 2016, 5(2): e1062208. DOI: 10.1080/2162402X.2015.1062208.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.